MINE-R regimen
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Mesna-Ifosfamide-Novantrone-Etoposide-Rituximab Regimen; MINE-R Regimen
Overview
Overview
MINE-R regimen refers to a regimen consisting of mesna, ifosfamide, mitoxantrone, etoposide, and rituximab used to treat relapsed or refractory Hodgkin’s lymphoma and non-Hodgkin’s lymphoma.[1]
Regimen
Regimen
MMesna
IIfosfamide
NMitoxantrone (Novantrone)
EEtoposide
RRituximab
References
References
- ↑ 1.0 1.1 Rehwald U, Schulz H, Reiser M, Sieber M, Staak JO, Morschhauser F; et al. (2003). “Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group”. Blood. 101 (2): 420–4. doi:10.1182/blood.V101.2.420. PMID 12509381.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH